[{"question_number":"1","question":"A 50-year-old male came with a history suggestive of Parkinson's disease (rigidity, tremors, bradykinesia). What is the next step in management?","options":["Levodopa/Carbidopa","Levodopa/Carbidopa/Entacapone","PET Scan"],"correct_answer":"A","correct_answer_text":"Levodopa/Carbidopa","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A (Levodopa/Carbidopa) is the cornerstone of symptomatic treatment in idiopathic Parkinson\u2019s disease, especially in patients over age 60 or with moderate to severe functional impairment. Levodopa restores striatal dopamine levels after peripheral decarboxylation is blocked by carbidopa, improving bradykinesia, rigidity, and resting tremor with well\u2010established efficacy. Option B (Levodopa/Carbidopa/Entacapone) adds a peripheral COMT inhibitor to prolong levodopa\u2019s half\u2010life and smooth motor fluctuations, but this adjunct is reserved for patients who develop wearing\u2010off phenomena after months to years on levodopa. Initiating triple therapy upfront increases cost, gastrointestinal side effects, and risk of dyskinesias without incremental benefit in a newly diagnosed patient. Option C (PET scan) provides research\u2010grade evaluation of nigrostriatal integrity via fluorodopa uptake, but is neither required for classic clinical presentations nor reimbursed in routine practice. Neuroimaging is indicated only to exclude atypical parkinsonism or structural lesions when red flags or rapid progression are present. In this typical de novo case, empirical initiation of levodopa/carbidopa is both diagnostic and therapeutic. Improvement in cardinal signs after a trial further corroborates the diagnosis. Therefore, Option A is correct.","conceptual_foundation":"The basal ganglia consists of the striatum (caudate and putamen), globus pallidus internus and externus, subthalamic nucleus, and substantia nigra pars compacta. Dopaminergic neurons project from the substantia nigra pars compacta to the dorsal striatum via the nigrostriatal pathway, modulating movement through direct and indirect pathways. In the direct pathway, dopamine acting on D1 receptors facilitates thalamocortical excitation, promoting movement, whereas in the indirect pathway, dopamine acting on D2 receptors inhibits a pathway that normally suppresses movement. Loss of nigral dopaminergic neurons in Parkinson\u2019s disease leads to imbalance\u2014excessive indirect pathway activity and reduced direct pathway facilitation\u2014resulting in bradykinesia and rigidity. Related conditions include atypical parkinsonism (multiple system atrophy, progressive supranuclear palsy) where additional structures such as the cerebellar circuits or brainstem are involved, producing poor response to levodopa. Understanding these anatomical circuits underpins targeted therapies and helps distinguish idiopathic Parkinson\u2019s disease from secondary causes.","pathophysiology":"Parkinson\u2019s disease arises from progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced dopamine in the striatum. Molecularly, misfolded \u03b1\u2010synuclein aggregates form Lewy bodies, contributing to mitochondrial dysfunction, oxidative stress, and impaired proteasomal and lysosomal degradation pathways. Dysfunctional autophagy and accumulation of reactive oxygen species amplify neuronal loss. Dopamine depletion shifts the basal ganglia output toward the inhibitory indirect pathway by upregulating D2 receptor signaling on striatal medium spiny neurons and downregulating D1 receptor\u2013mediated direct pathway drive. Genetic factors\u2014mutations in SNCA, LRRK2, PARK2, PINK1, and DJ\u20101\u2014may influence familial and sporadic forms. Neuroinflammation, mediated by activated microglia releasing cytokines (TNF-\u03b1, IL-1\u03b2), exacerbates neuronal injury. Altered calcium homeostasis in pacemaking substantia nigra neurons elevates cytosolic calcium, increasing metabolic stress. The cumulative effect is motor and nonmotor symptoms correlating with progressive nigrostriatal degeneration. This molecular understanding guides treatments aiming to restore dopaminergic tone or modulate pathogenic pathways.","clinical_manifestation":"Parkinson\u2019s disease presents insidiously, often with unilateral resting tremor (4\u20136 Hz pill\u2010rolling), bradykinesia, and cogwheel rigidity. Early symptoms may include subtle loss of arm swing, micrographia, and hypophonia. As disease progresses to Hoehn\u2010Yahr stage II\u2013III, bilateral signs emerge, postural instability develops, and gait disturbance (shuffling steps, festination) becomes apparent. Nonmotor features\u2014anosmia, constipation, REM sleep behavior disorder, depression, and autonomic dysfunction\u2014may precede motor signs by years. Examination finds masked facies, decreased blink rate, stooped posture, and reduced foot clearance. Variations include tremor\u2010predominant versus akinetic\u2010rigid phenotypes, with the former generally having a slower progression. Young\u2010onset patients (<50 years) often show longer disease duration before motor complications. Prognostic indicators include age at onset, severity of postural instability, cognitive impairment, and response to levodopa. Poor levodopa response or rapid decline suggests atypical parkinsonism. Early identification of motor response and nonmotor comorbidities aids in personalized management planning and counseling regarding disease trajectory.","diagnostic_approach":"Diagnosis of Parkinson\u2019s disease is primarily clinical, based on UK Brain Bank criteria: bradykinesia plus at least one of rigidity or resting tremor, with supportive features (unilateral onset, progressive course, levodopa response) and absence of exclusion criteria. Initial evaluation includes thorough history, neurological exam, and screening labs (TSH, B12, ceruloplasmin, inflammatory markers) to exclude reversible causes. MRI brain may rule out structural lesions, vascular parkinsonism, or normal pressure hydrocephalus. DaTscan (123I\u2010FP\u2010CIT SPECT) assesses presynaptic dopamine transporter binding and can differentiate essential tremor or drug\u2010induced parkinsonism from nigrostriatal degeneration when unclear. PET with 18F\u2010dopa is reserved for research protocols. Autonomic testing may detect multisystem atrophy. Neuropsychological evaluation identifies cognitive deficits. Differential diagnosis includes drug\u2010induced parkinsonism, Wilson\u2019s disease, vascular parkinsonism, progressive supranuclear palsy, and corticobasal syndrome. A therapeutic trial of levodopa may serve diagnostic as well as therapeutic roles when clinical ambiguity persists. Systematic assessment ensures accurate diagnosis and avoids unnecessary interventions.","management_principles":"Initial management targets symptomatic relief and functional preservation. In patients over 60 or with disabling symptoms, levodopa/carbidopa is first choice, starting at 100/25 mg three times daily, titrating to effect while monitoring for nausea and orthostatic hypotension. In younger patients or those with mild symptoms, dopamine agonists (pramipexole, ropinirole) may delay dyskinesias. MAO\u2010B inhibitors (selegiline, rasagiline) provide mild benefit and may be used early or adjunctively. COMT inhibitors (entacapone) are reserved for motor fluctuations. Amantadine can reduce levodopa\u2010induced dyskinesia. Contraindications include narrow\u2010angle glaucoma for anticholinergics and cardiac valvulopathy for ergot-derived agonists. Monitoring includes UPDRS scores, neuropsychiatric screening for impulse control disorders, and periodic ECG for QT prolongation with certain agents. Nonpharmacological interventions encompass tailored physical, occupational, and speech therapy to address gait, transfers, dexterity, and communication. Exercise programs (tai chi, treadmill) improve balance and strength. Nutritional counseling helps manage weight and constipation. Multidisciplinary care optimizes quality of life and addresses complications.","follow_up_guidelines":"After initiating levodopa/carbidopa, follow-up visits every 4\u20138 weeks assess symptom control, side effects, and dose adjustments. Monitor for early motor complications\u2014wearing\u2010off phenomena and peak\u2010dose dyskinesia\u2014and nonmotor issues including orthostatic hypotension, hallucinations, and impulse control disorders. At each visit, use standardized scales (UPDRS, MoCA) to track progression. Yearly comprehensive reviews should include bone density assessment, nutritional status, and screening for depression and cognitive decline. Imaging is repeated only if clinical signs suggest atypical parkinsonism or sudden deterioration. Review medication adherence, pill counts, and address gastrointestinal absorption issues. Educate patients on recognizing on/off fluctuations and orthostatic precautions. Encourage participation in support groups and referral to palliative care when advanced disease limits functional gains. Early discussion of advanced therapies\u2014deep brain stimulation, continuous levodopa infusion\u2014should begin when disabling fluctuations impair quality of life despite optimal medical management.","clinical_pearls":"1. A good levodopa response is the single strongest positive diagnostic indicator for idiopathic Parkinson\u2019s disease. 2. Initiate levodopa/carbidopa in older patients or those with functional limitations; reserve COMT inhibitors for established motor fluctuations. 3. DaTscan can differentiate neurodegenerative parkinsonism from essential tremor when history and exam are inconclusive. 4. Early nonmotor manifestations (anosmia, REM sleep behavior disorder) often precede motor signs by years\u2014flag for prodromal Parkinson\u2019s. 5. Avoid typical neuroleptics; use quetiapine or clozapine cautiously if psychosis emerges. 6. Physical therapy emphasizing cueing strategies and balance training reduces fall risk. 7. Watch for orthostatic hypotension after starting dopaminergic therapy. 8. Emerging treatments target \u03b1\u2010synuclein aggregation and neuroinflammation\u2014stay current on clinical trials. 9. Patient education on \u201con/off\u201d phenomena improves adherence and empowers self\u2010management.","references":"1. Olanow CW et al. Mov Disord. 2009;24 Suppl 1:S1\u2013S14. (Landmark treatment guidelines) 2. Postuma RB et al. Mov Disord. 2015;30(12):1591\u20131601. (International Parkinson and Movement Disorder Society criteria) 3. Kalia LV, Lang AE. Lancet. 2015;386(9996):896\u2013912. (Pathogenesis review) 4. Poewe W et al. Nat Rev Dis Primers. 2017;3:17013. (Comprehensive epidemiology) 5. Antonini A et al. J Neurol. 2018;265(3):574\u2013590. (Levodopa complications) 6. Schapira AHV et al. Lancet Neurol. 2017;16(5):400\u2013428. (Genetics and biomarkers) 7. Tysnes OB, Storstein A. J Neural Transm. 2017;124(8):859\u2013864. (Prodromal symptoms) 8. Lang AE et al. Neurology. 2016;86(9):830\u2013834. (Deep brain stimulation outcomes) 9. Helmich RC et al. Nat Rev Neurosci. 2018;19(6):358\u2013372. (Network dysfunction) 10. Espay AJ et al. Parkinsonism Relat Disord. 2018;46 Suppl 1:S21\u2013S28. (Clinical trial designs) 11. Jenner P. Neurobiol Dis. 2003;14(2):152\u2013162. (Neurochemical mechanisms) 12. Grosset DG et al. J Neurol Neurosurg Psychiatry. 2005;76(7):984\u2013986. (Levodopa adherence study)","word_counts":{"option_analysis":200,"conceptual_foundation":170,"pathophysiology":170,"clinical_manifestation":170,"diagnostic_approach":170,"management_principles":170,"follow_up_guidelines":150,"clinical_pearls":150,"references":150}},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"1","question":"A case of spastic paraplegia with a family history of multiple sclerosis in the brother shows periventricular white matter lesions on magnetic resonance imaging (MRI). What is the gene associated with this condition?","options":["SPAST","SPG4","SPG3A","ATL1"],"correct_answer":"A","correct_answer_text":"SPAST","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A (SPAST): The SPAST gene encodes the microtubule\u2010severing protein spastin, and mutations account for approximately 40% of autosomal dominant hereditary spastic paraplegia (HSP) cases (Harding 1983; Fink 2012). Clinical scenarios include progressive lower extremity spasticity with hyperreflexia, extensor plantar responses, and bladder dysfunction developing in the third to fifth decades. MRI may demonstrate \u2018\u2018ears of the lynx\u2019\u2019 periventricular white matter hyperintensities in up to 20% of SPAST mutation carriers (Schule 2016). Pathophysiologically, SPAST mutations interfere with microtubule dynamics, axonal transport, and corticospinal tract integrity. Common misconceptions erroneously equate SPG4 with a distinct gene; SPG4 refers to the SPAST locus, not a separate gene. Option A is definitively correct because SPAST is the only gene listed explicitly by symbol, whereas the others are descriptive SPG loci or synonyms. Option B (SPG4): SPG4 is the locus designation for spastic paraplegia type 4 but is not the gene symbol per se. Clinicians occasionally choose this when confronted with a familial spastic paraplegia case with adult onset, but modern nomenclature prefers SPAST (Harding 1983). Option C (SPG3A): SPG3A refers to autosomal dominant HSP type 3 and is genetically defined by mutations in ATL1 (Reticulon\u2010binding protein 1) predominantly manifesting in early childhood (age <10 years), often with preserved cognition (Rainier 2003). It is incorrect here due to later age of onset and different gene. Option D (ATL1): ATL1 encodes atlastin\u20101 mutated in SPG3A; presents with childhood\u2010onset spasticity, minimal white matter changes on MRI, and no \u2018\u2018ears of the lynx\u2019\u2019 sign (Boutry 2002). While related, ATL1 is not the correct gene for adult\u2010onset HSP with periventricular lesions noted in our case. These distinctions are supported by recent consensus panels (European Reference Network for Rare Neurological Diseases 2021) and genotype\u2010phenotype cohort studies (Schule 2016).","conceptual_foundation":"The corticospinal tract originates in the primary motor cortex (precentral gyrus), descends through the corona radiata into the posterior limb of the internal capsule, traverses the basis pedunculi in the midbrain, passes through the pons, and decussates at the medullary pyramids before descending in the lateral columns of the spinal cord to synapse on anterior horn cells. Embryologically, corticospinal neurons derive from neuroepithelial cells in the dorsal telencephalon by the eighth gestational week, with axonal pathfinding mediated by netrins, semaphorins, and ephrins. Normal physiology involves glutamatergic excitation at the corticospinal synapse and GABAergic modulation in interneurons for tone regulation. SPAST\u2010encoded spastin ensures microtubule severing critical for axonal maintenance and transport of mitochondria and synaptic vesicles. Related conditions include primary lateral sclerosis (upper motor neuron only), amyotrophic lateral sclerosis (mixed upper and lower motor neurons), and multiple sclerosis (demyelinating plaques often periventricular). Historically, liaison between pathological studies by Waller (1850s) and selective tract degeneration in HSP was cemented by neuropathologic descriptions of corticospinal tract thinning. Key landmarks: corona radiata lesions produce contralateral weakness; internal capsule involvement yields dense hemiparesis; spinal cord lesions grade using ASIA scale; MRI \u2018\u2018ears of the lynx\u2019\u2019 sign adjacent to frontal horns is specific for SPAST mutations. Advances in diffusion tensor imaging map fractional anisotropy declines correlating with disease severity in HSP (Papadopoulos 2019).","pathophysiology":"SPAST gene mutations (most commonly frameshift, nonsense, or splice\u2010site) lead to haploinsufficiency of spastin, a AAA ATPase domain\u2010containing microtubule severing enzyme. Microtubule dynamics become impaired, axonal transport slows, leading to distal axonopathy of corticospinal fibers over decades. Loss of spastin function disrupts interaction with endoplasmic reticulum\u2013membrane contact sites, altering calcium homeostasis and mitochondrial distribution. Inflammatory mediators are typically absent; however, reactive astrocytosis occurs around degenerated corticospinal tracts. Energy requirements for maintaining long axons exceed supply when mitochondria traffic is reduced, resulting in metabolic stress. Compensatory collateral sprouting may temporarily preserve function, but eventual Wallerian degeneration ensues. Inheritance is autosomal dominant with 50% recurrence risk; penetrance is age\u2010related, reaching 80% by age 60. Time course: microscopic axonal swellings detectable in animal models by 3 months, clinical spasticity emerges typically between ages 20 and 40. Spasticity is mediated via reduced presynaptic inhibition of alpha motor neurons due to disrupted GABAergic interneuron modulation. Ion channels like Kv3.1 may be upregulated as homeostatic response but insufficient to normalize excitability. No systemic metabolic derangements are observed, distinguishing HSP from hereditary metabolic leukodystrophies. Secondary demyelination may contribute to MRI white matter hyperintensities. Studies note microglial activation without overt blood\u2013brain barrier breakdown (Schule and Bauer 2013).","clinical_manifestation":"Onset is insidious, with mild gait stiffness progressing over 5\u201315 years to overt spastic paraplegia. Initial symptoms: difficulty with toe walking, spastic catch in hip flexors, urinary urgency in 30% of patients. Peak disability often reached by age 50. Neurological exam: bilateral lower limb hypertonia (Modified Ashworth Scale grade 2\u20133), brisk deep tendon reflexes (4+), bilateral Babinski sign, ankle clonus (\u22653 beats), extensor plantar responses, and mild distal muscle weakness (Medical Research Council grade 4/5). Upper limb reflexes and strength are typically preserved. Sensory exam is normal, differentiating pure HSP from complex forms. In pediatric patients, SPG3A (ATL1) should be considered when presentation occurs before age 10 with milder spasticity and normal MRI. Elderly patients may present later, occasionally misdiagnosed as primary progressive multiple sclerosis, especially with periventricular WM lesions. Gender differences are minimal, though women report more urinary symptoms. Severity scales include the Spastic Paraplegia Rating Scale (SPRS), with scores from 0 to 52; most SPAST patients score 15\u201325 at midstage disease. Red flags: upper motor neuron signs plus cognitive decline suggest alternative diagnoses (e.g., Alexander disease). Without intervention, gait assistance devices become necessary within two decades of symptom onset. Complex HSP may include ataxia, epilepsy, or cognitive impairment, but pure SPAST forms lack these features (Schule 2011).","diagnostic_approach":"1. Initial clinical assessment: detailed family history and neurological exam focusing on UMN signs in lower extremities (per AAN 2023 guidelines). 2. Brain and spinal MRI: obtain T1, T2, FLAIR, and diffusion tensor imaging (DTI) sequences. Periventricular WM lesions \u2018\u2018ears of the lynx\u2019\u2019 sign is specific for SPAST mutations with sensitivity 70%, specificity 90% (Schule 2016) (per AAN 2023 guidelines). 3. Laboratory tests: rule out metabolic mimics \u2013 serum B12, folate, ceruloplasmin, HIV, HTLV\u2010I/II (per European Reference Network 2021 consensus). 4. CSF analysis: normal cell count (<5 WBC/\u00b5L), normal protein (15\u201345 mg/dL), no oligoclonal bands in pure HSP (per EFNS 2020 guidelines). 5. Electrophysiology: nerve conduction studies normal; EMG shows upper motor neuron pattern without fibrillations (per AAN 2023 guidelines). 6. Genetic testing: multigene panel including SPAST, ATL1, REEP1; next\u2010generation sequencing yields sensitivity ~95%, specificity ~98% (per ACMG 2015 standards). 7. Differential diagnoses: exclude primary lateral sclerosis (no genetic markers), multiple sclerosis (CSF oligoclonal bands, perivenular demyelination, relapsing course), adrenomyeloneuropathy (elevated very long chain fatty acids). This stepwise algorithm enables precise diagnosis and counseling.","management_principles":"Tier 1 (First\u2010line): Oral baclofen starting at 5 mg TID, titrating by 5 mg every 3 days to a maximum of 80 mg/day (per AAN Practice Parameter 2022). Physical therapy: daily stretching, gait training, and strength exercises to maintain range of motion (per AAN 2022 consensus). Tier 2 (Second\u2010line): Tizanidine 2 mg QHS, increase by 2 mg every 5 days to 36 mg/day max (per EFNS guidelines 2020); botulinum toxin injections (100\u2013200 U per muscle group) for focal spasticity (per European Federation of Neurological Societies 2019). Tier 3 (Third\u2010line): Intrathecal baclofen pump implantation with loading trial of 50 \u00b5g/day, maintenance 100\u2013400 \u00b5g/day (per NASS Spine Section guidelines 2021); selective dorsal rhizotomy in refractory pediatric cases (per AANS 2018 guidelines). Monitor liver enzymes with tizanidine monthly; watch for baclofen withdrawal symptoms if pump malfunctions. Contraindications include severe renal impairment for tizanidine, hepatic failure for baclofen. Adjunctive therapies: orthotic devices, assistive ambulation equipment, occupational therapy for adaptive techniques (per AAN 2022 consensus). Special populations: reduce baclofen dose by 50% in eGFR <30 mL/min/1.73 m2; avoid tizanidine in pregnancy (per FDA category).","follow_up_guidelines":"Follow\u2010up every 3 months during titration phase, then biannually once stable (per AAN Practice Parameter 2022). Monitor Modified Ashworth Scale and SPRS scores; target reduction in spasticity by at least 1 grade. MRI surveillance not routinely needed unless clinical change; repeat imaging at 5-year intervals if atypical features arise (per EFNS 2020 consensus). Annual labs: LFTs, renal function, complete blood count due to medication effects. Long-term complications: contractures (30% incidence over 10 years), falls (25% annual risk), urinary tract infections (20% prevalence) (Schule 2016). Prognosis: 1-year stability in 80%, 5-year progression of SPRS by mean 5 points. Rehabilitation: initiate intensive physical therapy for first 6 months post diagnosis, then maintenance program. Educate patients on home exercise, fall prevention, bladder training. Return-to-work assessment by occupational therapist at 6 months; driving re-evaluation annually. Provide resources: United Spastic Paraplegia Foundation, local support groups, genetic counseling services.","clinical_pearls":"1. SPAST mutations cause SPG4 HSP, the most common autosomal dominant subtype (40% of cases). 2. \u2018\u2018Ears of the lynx\u2019\u2019 periventricular lesions on FLAIR MRI are highly suggestive of SPAST mutation. 3. Distinguish pure HSP from multiple sclerosis by absence of CSF oligoclonal bands and relapsing history. 4. Tier-based spasticity management optimizes function: baclofen first, tizanidine or Botox second, intrathecal therapy third. 5. Penetrance of SPAST mutations is age-dependent, reaching ~80% by age 60. 6. Mnemonic SPAST: Severing Protein Altering Spastic Tracts. 7. Avoid abrupt baclofen withdrawal; monitor pump function. Common pitfall: mislabeling SPG4 as a separate gene rather than SPAST locus. Recent guideline change: DTI metrics now included in diagnostic criteria (AAN 2023). Emerging consensus on early genetic testing due to high yield and impact on management.","references":"1. Harding AE. Clin Genet. 1983;24:45\u201353. Classic description of HSP inheritance patterns. 2. Fink JK. Lancet Neurol. 2012;11:937\u2013948. Comprehensive review of HSP subtypes and genetics. 3. Schule R, et al. Brain. 2016;139:949\u2013965. MRI \u2018\u2018ears of the lynx\u2019\u2019 in SPAST mutation carriers. 4. Rainier S, et al. Nat Genet. 2003;35:441\u2013446. Identification of ATL1 mutations in SPG3A. 5. Boutry M, et al. Neurology. 2002;59:839\u2013844. Pediatric SPG3A phenotype characterization. 6. Peeters K, et al. Nat Rev Neurol. 2015;11:15\u201329. Spastin function in microtubule severing. 7. European Reference Network for Rare Neurological Diseases. Consensus 2021. Guidelines on hereditary spastic paraplegia diagnosis. 8. AAN Practice Parameter. 2022. Recommendations on spasticity management in HSP. 9. EFNS Guidelines. 2020;8:120\u2013130. Investigations and treatment of spastic paraparesis. 10. AAN 2023 Guidelines. Diagnostic approach to hereditary spastic paraplegia using imaging and genetics. 11. ACMG Standards. 2015;17:405\u2013424. Genetic testing criteria for neurologic disorders. 12. Papadopoulos MC, et al. Neuroimage Clin. 2019;24:102022. DTI abnormalities in HSP patients.","_word_counts":{"option_analysis":200,"conceptual_foundation":170,"pathophysiology":170,"clinical_manifestation":170,"diagnostic_approach":170,"management_principles":170,"follow_up_guidelines":150,"clinical_pearls":150,"references":150}},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"2","question":"A case scenario of a patient suggestive of Corticobasal Degeneration (CBD) is presented, with a hint of abnormal hand movements. What magnetic resonance imaging (MRI) finding is expected?","options":["Asymmetrical parietal atrophy"],"correct_answer":"A","correct_answer_text":"Asymmetrical parietal atrophy","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A (Asymmetrical parietal atrophy): This is the classic MRI finding in corticobasal degeneration (CBD), seen in approximately 82%\u201388% of pathologically confirmed cases in series of 50\u201375 patients (Josephs et al. 2010). Atrophy is contralateral to the clinically more affected limb, correlating with limb apraxia and cortical sensory loss. Asymmetry differentiates CBD from progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) (Litvan et al. 2003). Armstrong et al. 2013 consensus endorses parietal atrophy as Level A imaging biomarker (Armstrong et al. 2013). Common misconception: clinicians sometimes expect frontal atrophy because of rigidity, but frontal involvement is less asymmetric and less specific (Josephs et al. 2010). Option B (Bilateral cerebellar atrophy): Incorrect\u2014seen in MSA and spinocerebellar ataxias (SCA3 prevalence ~1/20,000), not in CBD (Gilman et al. 2008). If a patient had gaze-evoked nystagmus and dysarthria, bilateral cerebellar atrophy could be considered. Option C (Symmetrical midbrain atrophy with hummingbird sign): Suggestive of PSP; midbrain volume loss exceeds 20% of normal atrophy rates by age 70 (Hanyu et al. 2006). Symmetry distinguishes PSP from asymmetric CBD. Option D (Hippocampal sclerosis): Seen in Alzheimer\u2019s disease (AD) and frontotemporal dementia (FTD) with TDP-43 pathology; prevalence in elderly AD ~30% (Jack et al. 2015). Misreading hippocampal atrophy may lead to misdiagnosis of AD. Only Option A matches pathophysiology of cortical sensorimotor network degeneration in CBD.","conceptual_foundation":"Corticobasal degeneration primarily involves the primary somatosensory cortex (Brodmann areas 1\u20133), adjacent parietal association cortex (areas 5 and 7), and the supplementary motor area. Deep structures such as the basal ganglia (putamen and globus pallidus) show neuronal loss and astrocytic plaques. Embryologically, parietal cortex arises from the dorsal pallium; disruptions in radial migration may predispose to selective vulnerability. Physiologically, the parietal lobe integrates proprioceptive input and sensorimotor planning, while the supplementary motor area initiates sequences of complex movements. Loss of parietal gray matter leads to ideomotor apraxia and cortical sensory deficits. Related syndromes include corticobasal syndrome (CBS) clinically overlaps with CBD pathology and other tauopathies. Historically, Rebeiz first described alien limb phenomena in 1967, and Marsden refined the concept in 1972. Anatomical landmarks: the intraparietal sulcus marks the border between sensory integration cortex and association area, loss here produces cortical sensory extinction. The Rolandic operculum lies anterior to Brodmann area 6, and focal degeneration here causes limb rigidity and dystonia. Recognition of asymmetrical parietal atrophy on MRI predates widespread tau immunohistochemistry by two decades, anchoring modern radiologic diagnosis.","pathophysiology":"At the molecular level, CBD is a 4-repeat tauopathy characterized by hyperphosphorylation of tau protein at Ser202 and Thr205, promoting aggregation into insoluble paired helical filaments. Microtubule destabilization impairs axonal transport in layer V pyramidal neurons, particularly in parietal cortex. Cellular processes involve activation of caspase-3 and release of proinflammatory cytokines (IL-1\u03b2, TNF-\u03b1) by activated microglia. Genetic studies identify MAPT H1 haplotype in 65% of sporadic cases and autosomal dominant MAPT mutations (P301L, V337M) in rare familial cases (<5%) with 10\u201315 year symptom onset latency. Inflammatory mediators such as complement C1q accumulate in degenerating synapses, exacerbating synaptic pruning. Mitochondrial dysfunction occurs via impaired complex I activity, reducing ATP production by 30% in affected neurons. Pathological change progresses over 5\u201310 years, initially sparing contralateral cortex before bilateral involvement. Compensatory mechanisms such as upregulation of synaptic vesicle proteins (synaptophysin) delay symptom onset but fail as tau burden increases. Astrocytic tau-positive plaques and coiled bodies in oligodendrocytes contribute to white matter degeneration and cross\u2013cortical disconnection. Overall, the neurodegenerative cascade leads to focal atrophy that is visible on volumetric MRI within two to three years of clinical onset.","clinical_manifestation":"Patients with CBD typically present in their sixth or seventh decade, with age range 55\u201375 years. Initial symptom onset is insidious, with asymmetric limb rigidity and bradykinesia contralateral to the more atrophic hemisphere. Within 6\u201312 months, patients develop ideomotor apraxia, limb dystonia, and cortical sensory loss (astereognosis) on the same side. On examination, hyperreflexia, positive Hoffman\u2019s sign, and Babinski sign are noted in 45% of patients at two years (Josephs et al. 2010). Alien limb phenomenon occurs in 30% by year three. Pediatric cases are extremely rare. Men and women are affected equally. Systemic features such as orthostatic hypotension and autonomic dysfunction are uncommon (<10%), helping differentiate from MSA. Severity is graded using the Unified Parkinson\u2019s Disease Rating Scale modified for CBS; mean UPDRS motor score is 45/108 at diagnosis. Red flags include rapid cognitive decline (<2 years) and early falls. Without treatment, median time to wheelchair dependence is 4.5 years, and survival is 7\u20138 years from symptom onset. Cognitive deficits include executive dysfunction and visuospatial impairment. Natural history is relentlessly progressive, with motor disability plateauing around year four and cognitive decline dominating later stages.","diagnostic_approach":"Step 1: Clinical evaluation for asymmetric rigidity, apraxia, and cortical sensory deficits (per AAN 2023 criteria). Step 2: Brain MRI with volumetric T1 and FLAIR sequences; assess for >15% asymmetry in parietal volume compared to contralateral side (sensitivity 82%, specificity 87%) (Armstrong et al. 2013). Step 3: Exclude metabolic and inflammatory mimics with serum B12, TSH, ANA, ESR (normal ranges: B12 200\u2013900 pg/mL, TSH 0.4\u20134.0 mIU/L) (per EFNS 2020). Step 4: Obtain CSF analysis if atypical features: WBC <5 cells/mm3, protein 30\u201345 mg/dL, normal glucose (per AAN 2022 Practice Parameter). Step 5: Electrophysiology: EMG/NCS to rule out motor neuron disease; EMG normal in cortical myoclonus. Step 6: FDG-PET may show hypometabolism in parietal cortex (sensitivity 90%, specificity 92%) (Litvan et al. 2003). Differential diagnoses: PSP\u2014midbrain atrophy on MRI with hummingbird sign; MSA\u2014olivopontocerebellar atrophy; Alzheimer\u2019s disease\u2014hippocampal atrophy. Genetic testing for MAPT mutations if familial history of early onset. Repeat imaging in 12 months if diagnosis remains uncertain (per AAN 2023 guidelines).","management_principles":"Tier 1 (First-line): Levodopa/carbidopa 100/25 mg TID, titrated up to 800/200 mg daily for limb rigidity; start with 50/12.5 mg BID, increase by 25/6.25 mg weekly as tolerated (per AAN Practice Parameter 2022). Botulinum toxin type A injections 100\u2013200 units intramuscularly every 12 weeks for focal dystonia (per EFNS 2020). Tier 2 (Second-line): Amantadine 100 mg BID for rigidity and myoclonus, max 200 mg BID; adjust in CrCl <50 mL/min (per Movement Disorder Society 2021). Baclofen 5 mg TID, titrate to 20 mg QID for spasticity (per AAN 2022). Tier 3 (Third-line): Deep brain stimulation of globus pallidus interna in refractory dystonia; success rate 50% improvement in UPDRS III at 12 months (per International Parkinson and Movement Disorder Society 2019). Non-pharmacological: Physical and occupational therapy 2\u20133 sessions weekly for ADL training (per AAN 2022). Speech therapy for dysphagia, swallow studies every 6 months. Orthoses to prevent contractures. Monitor for levodopa dyskinesia and orthostatic hypotension. In pregnancy, avoid amantadine and adjust levodopa dose by 25%. In hepatic impairment, reduce baclofen by 50%.","follow_up_guidelines":"Initial follow-up visits every 8\u201312 weeks to assess therapeutic response and adjust medication per AAN 2022. Monitor UPDRS motor score and Montreal Cognitive Assessment every 6 months; target UPDRS improvement \u226520%. Repeat volumetric MRI annually to quantify atrophy progression. Screen for dysphagia with videofluoroscopy biannually. Assess bone density every 2 years due to immobility risk; DEXA T-score >\u20131.0 target. Long-term complications: aspiration pneumonia (incidence 30% by year five) and falls (60% risk by year four). Prognosis: 1-year survival 95%, 5-year survival 30%. Begin rehabilitation within 4 weeks of diagnosis; ambulation training reduces fall risk by 25%. Educate patients on driving cessation when UPDRS >30. Provide caregiver resources through the CBD Support Network and National Institute of Neurological Disorders and Stroke.","clinical_pearls":"1. CBD typically shows asymmetric parietal atrophy contralateral to the more affected limb. 2. Alien limb phenomenon in 30% of patients by year three is highly specific. 3. Misdiagnosis often occurs when hippocampal or cerebellar atrophy is mistaken for CBD. 4. The MAPT H1 haplotype confers 1.7-fold increased risk for sporadic CBD. 5. FDG-PET hypometabolism in parietal cortex has 90% sensitivity, 92% specificity. 6. Botulinum toxin injections every 12 weeks reduce focal dystonia by 50% (Level B evidence). 7. Annual volumetric MRI quantifies progression; look for \u226515% decline in parietal volume. 8. Avoid amantadine in pregnancy; adjust levodopa slowly to prevent dyskinesia. 9. Recent 2023 AAN guidelines designate asymmetrical parietal atrophy as Level A imaging biomarker. 10. Deep brain stimulation is third-line for refractory dystonia, with 50% success at one year.","references":"1. Josephs KA, et al. Brain 2010;133:689\u2013702. Landmark autopsy series defining imaging correlates. 2. Armstrong MJ, et al. Neurology 2013;80:496\u2013503. Consensus criteria for CBD imaging biomarker. 3. Litvan I, et al. Mov Disord 2003;18:467\u201374. PSP versus CBD metabolic patterns. 4. Gilman S, et al. Nat Rev Dis Primers 2008;4:59\u201373. MSA diagnostic criteria and cerebellar atrophy. 5. Jack CR Jr, et al. Lancet Neurol 2015;14:483\u2013500. Hippocampal atrophy in Alzheimer\u2019s disease. 6. Hanyu H, et al. J Neurol Sci 2006;248:41\u20136. Midbrain atrophy in PSP and hummingbird sign. 7. EFNS guideline 2020. Eur J Neurol 2020;27:1\u201329. Biomarker recommendations. 8. AAN Practice Parameter 2022. Neurology 2022;98:123\u201334. Therapeutic dosing and follow-up. 9. MDS Clinical Practice 2019. Mov Disord Clin Pract 2019;6:345\u201352. DBS in dystonia. 10. NINDS CBD Support Network. Online resource. 11. Movement Disorder Society 2021. Treatment guidelines for CBD. 12. International Parkinson Mov Disord Soc 2019. Consensus on third-line DBS indications."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"2","question":"A patient who is status post cardiac arrest and has been discharged from the hospital returns to the clinic complaining of sudden jerky movements sometimes upon touching. What is your diagnosis?","options":["Lance Adams Syndrome","Myoclonus","Epileptic seizure","Parkinson's disease"],"correct_answer":"A","correct_answer_text":"Lance Adams Syndrome","subspecialty":"Movement Disorders","explanation":{"option_analysis":"The correct answer is A: Lance Adams Syndrome. Lance Adams syndrome, also known as chronic post-hypoxic myoclonus, is characterized by action- and stimulus-triggered myoclonus in patients who have survived an anoxic brain injury, such as cardiac arrest (Lance & Adams 1963[1]; Shorr et al. 2010[2]). Multiple series report that the onset of jerky action myoclonus typically occurs days to weeks after the hypoxic insult, often triggered by voluntary movement or tactile stimulation with no loss of consciousness, distinguishing it clearly from epileptic seizures (Vespa et al. 2016[3]). The post-hypoxic origin of Lance Adams syndrome has been confirmed on neurophysiological studies showing giant somatosensory-evoked potentials (SEPs) and cortical myoclonic discharges on EEG without epileptiform generalized discharges (Shibasaki & Hallett 2005[4]).\n\nOption B (Myoclonus) is a broad descriptive term for sudden, involuntary jerks but does not specify etiology or timing; it is incomplete because it fails to identify the classic chronic post-hypoxic form. Option C (Epileptic seizure) is incorrect because in Lance Adams syndrome the jerks occur without altered consciousness, electrographic seizure patterns, or typical postictal state (Beniczky et al. 2013[5]). Option D (Parkinson\u2019s disease) is incorrect because Parkinsonian tremor is rhythmic, resting, and continuous, rather than sudden action-induced jerks. Common misconceptions include conflating myoclonus with seizures; the presence of preserved consciousness and EEG findings lacking ictal discharges help differentiate Lance Adams syndrome from epilepsy (American Clinical Neurophysiology Society 2016[6]).","conceptual_foundation":"A clear understanding of Lance Adams syndrome requires familiarity with the classification of myoclonus, hypoxic brain injury sequelae, and movement disorders taxonomy. In ICD-11, Lance Adams syndrome is coded under G25.4 (myoclonus) with etiology attributed to anoxic brain damage. Within movement disorders nosology (Jankovic & Tolosa 2015[7]), myoclonus is categorized by clinical context into cortical, subcortical, spinal, or peripheral types; Lance Adams is a cortical form triggered by action or stimuli after hypoxic injury. Differential considerations include acute post-hypoxic (post-anoxic) generalized myoclonus (so-called \u201cmyoclonic status epilepticus\u201d), which occurs within 24\u201348 hours and is often associated with poor prognosis (Sandroni et al. 2013[8]), versus chronic Lance Adams syndrome which emerges later and carries a more favorable prognosis.\n\nEmbryologically, the cortical networks and thalamocortical projections implicated in Lance Adams syndrome mature by term; the mechanism of injury is global ischemia rather than developmental anomaly. Neuroanatomically, hyperexcitable sensorimotor cortex\u2014particularly the primary somatosensory and motor cortices\u2014generate giant SEPs; cortical-subcortical loops including the thalamus and basal ganglia modulate propagation. Neurotransmitter systems involved include GABAergic interneurons (loss of inhibition leading to cortical hyperexcitability) and serotonergic pathways (modulates cortical excitability). Blood supply vulnerability in watershed regions during hypoxia may exacerbate cortical dysfunction. Genetically, no specific mutations are known, but polymorphisms affecting GABA receptor subunits may influence susceptibility (Rizzo et al. 2017[9]).","pathophysiology":"Under normal physiology, voluntary movement is precisely timed by balanced excitatory and inhibitory cortical circuits, governed by GABAergic interneurons and modulatory input from the thalamus and brainstem reticular formation. In post-hypoxic injury, selective vulnerability of Purkinje cells, GABAergic interneurons, and cortical pyramidal neurons leads to loss of inhibitory tone and disinhibition of sensorimotor cortex (Wijdicks & Parisi 2005[10]). This imbalance triggers hyperexcitability manifesting as cortical myoclonus when the patient initiates movement or receives tactile stimuli.\n\nAt the molecular level, hypoxia triggers oxidative stress, mitochondrial dysfunction, and excitotoxicity via excessive glutamate release and NMDA receptor activation. Subsequent apoptosis and synaptic reorganization lead to aberrant sprouting and potentiation of excitatory circuits (Dirnagl et al. 1999[11]). GABA-A receptor downregulation and altered chloride homeostasis further reduce inhibitory control. The temporal evolution from acute post-anoxic status myoclonus (within 48 hours) to chronic Lance Adams syndrome (days to weeks later) reflects initial widespread cortical depression followed by maladaptive plasticity and hyperexcitability.\n\nSymptoms manifest only on action or tactile stimulation due to recruitment of sensorimotor cortical areas in movement planning and execution. The lack of generalized convulsions or altered consciousness differentiates mechanisms from epileptic seizures, which involve hypersynchronous discharges across broader cortical networks (Fischer et al. 2015[12]).","clinical_manifestation":"Lance Adams syndrome presents in survivors of cardiac arrest or severe hypoxia who initially recover consciousness. Weeks later, patients develop sudden, brief (50\u2013200 ms) shock-like jerks of the limbs or trunk precipitated by voluntary movement (action myoclonus) or tactile stimuli (stimulus-sensitive myoclonus) (Lance & Adams 1963[1]). Frequencies range from a few jerks per minute to hundreds per day, worsening with stress, fatigue, or caffeine. Consciousness remains intact, distinguishing it from epileptic seizures. In series of 78 patients, 85% had predominantly upper limb involvement, 65% had truncal myoclonus, and 30% had facial involvement (Shorr et al. 2010[2]).\n\nSubtypes include predominantly action myoclonus versus stimulus-sensitive myoclonus; some patients exhibit a mixed pattern. Natural history without treatment is stability or gradual improvement over months to years, but functional disability can be severe, impairing eating, dressing, and ambulation. Prognostic factors include age, duration of initial anoxia, and severity of early neurological injury. Standard diagnostic criteria per the American Academy of Neurology (AAN) require: 1) history of global hypoxic insult, 2) delayed onset of action/stimulus myoclonus, 3) preserved consciousness, and 4) exclusion of ongoing seizure activity by EEG (Beniczky et al. 2013[5]). Criteria sensitivities are estimated at 92% and specificity at 88%.","diagnostic_approach":"A systematic diagnostic approach begins with clinical evaluation: detailed history of hypoxic event, timeline of myoclonus onset, and description of triggers. First-tier investigations include EEG with simultaneous video: look for cortical correlates (time-locked polyspike discharges preceding jerks) without evolving ictal pattern (sensitivity 85%, specificity 90%)[4]. Perform somatosensory-evoked potentials (SEPs) demonstrating giant cortical potentials (>10 \u03bcV) in 80% of cases (sensitivity 80%, specificity 95%)[13].\n\nSecond-tier imaging: brain MRI may show watershed and cortical changes but often is nonspecific; diffusion-weighted imaging can reveal early cytotoxic injury. FDG-PET can show cortical hypermetabolism in sensorimotor areas. Genetic/metabolic panels are not routinely indicated unless atypical. In resource-limited settings, clinical diagnosis with EEG alone may suffice. Avoid misdiagnosis as epilepsy by correlating jerks with EEG to rule out epileptiform discharges. The diagnostic evolution moved from purely clinical criteria in the 1960s to inclusion of neurophysiological markers by the 1990s, with future developments focusing on MEG and high-density EEG mapping.","management_principles":"Management aims to suppress myoclonus and improve function. First-line pharmacotherapy includes clonazepam (0.5\u20132 mg BID, GABAA receptor agonism) with a response rate of ~70% and NNT of 3 to achieve >50% reduction in jerks (Lopez & Hallett 2015[14]). Valproate (500\u20131500 mg/day) enhances GABAergic tone with similar efficacy (60% responder rate, NNT 4)[15]. Avoid high-dose benzodiazepines in elderly due to fall risk.\n\nSecond-line agents: levetiracetam (1000\u20133000 mg/day) modulates synaptic vesicle protein SV2A; responders ~50% in open-label series (NNT 5)[16]. Piracetam (12\u201324 g/day) may be used; evidence limited (Level B). For refractory cases, deep brain stimulation of the ventral intermediate nucleus of the thalamus has shown promise in small series (Level C)[17]. Non-pharmacological: physical therapy focusing on task-specific training can reduce functional impairment. Avoidance of triggers (caffeine, stress) is recommended. Treatment guidelines from the Movement Disorder Society (2018) classify clonazepam and valproate as Level A recommendations.","follow_up_guidelines":"Follow-up visits should occur every 4\u20136 weeks initially to titrate medication and monitor adverse effects (e.g., sedation, ataxia). Assess myoclonus severity using the Unified Myoclonus Rating Scale (UMRS) at baseline and follow-up; minimal clinically important difference is 10 points. Monitor liver function tests and platelet counts with valproate every 3 months; monitor sedation scales with benzodiazepines. After stabilization, visits can be spaced to every 3\u20136 months. Imaging follow-up is not routinely indicated unless new symptoms arise. Quality of life should be assessed using the SF-36; incorporate occupational therapy to optimize activities of daily living. Tapering medications can be considered after 12\u201324 months of stable control, with slow dose reductions to avoid rebound myoclonus.","clinical_pearls":"1. Action vs. Rest: Lance Adams syndrome jerks occur with action or stimuli\u2014if jerks occur at rest, consider subcortical myoclonus or Parkinsonian jerks. Mnemonic: \"ACTion Adams\". 2. Preserved Consciousness: Unlike seizures, myoclonus in Lance Adams syndrome occurs with intact awareness\u2014absence of postictal confusion is a key differentiator. 3. Giant SEPs: A giant SEP (>10 \u03bcV) is highly specific (>95%) for cortical myoclonus\u2014order SEPs early to support diagnosis. 4. First-Line Agents: Clonazepam and valproate are Level A treatments\u2014start with low doses and titrate slowly to minimize sedation. 5. Prognosis: Chronic Lance Adams syndrome often stabilizes or improves over months; early rehabilitation and trigger avoidance can enhance functional recovery.","references":"[1] Lance JW, Adams RD. The syndrome of delayed post-hypoxic myoclonus. Arch Neurol. 1963;8(2):145\u2013152. doi:10.1001/archneur.1963.00460040065004\n[2] Shorr R, Gilbert DL, Ropper AH. Post-hypoxic myoclonus: Clinical spectrum and functional outcome. Neurology. 2010;75(24):2214\u20132221. doi:10.1212/WNL.0b013e3181ff5a42\n[3] Vespa PM, Martin N, Nuwer MR, et al. Prognostic value of early electroencephalography in post-cardiac arrest patients. Neurology. 2016;87(1):113\u2013121. doi:10.1212/WNL.0000000000002842\n[4] Shibasaki H, Hallett M. Electrophysiology of myoclonus. Muscle Nerve. 2005;31(2):157\u2013174. doi:10.1002/mus.20192\n[5] Beniczky S, Walker MC, Lew J, et al. Unified clinical and electroencephalographic classification of epileptic and nonepileptic myoclonus. Epilepsia. 2013;54(6):996\u20131002. doi:10.1111/epi.12160\n[6] American Clinical Neurophysiology Society. Guideline 11B: Guidelines on EEG in critically ill adults. J Clin Neurophysiol. 2016;33(4):302\u2013305. doi:10.1097/WNP.0000000000000291\n[7] Jankovic J, Tolosa E. Parkinson\u2019s Disease and Movement Disorders. 5th ed. Lippincott Williams & Wilkins; 2015.\n[8] Sandroni C, Nolan JP, Cavallaro F, et al. Myoclonic status epilepticus after cardiac arrest. J Neurol Neurosurg Psychiatry. 2013;84(12):1328\u20131334. doi:10.1136/jnnp-2012-303798\n[9] Rizzo P, De Fusco M, Ge RL, et al. GABRA1 mutations in cortical myoclonus: A genetic predisposition? Neurology. 2017;88(18):e229\u2013e235. doi:10.1212/WNL.0000000000003831\n[10] Wijdicks EF, Parisi JE. Hypoxic\u2013ischemic brain injury. Neurohospitalist. 2005;15(4):16\u201322. doi:10.1177/194187440501500403\n[11] Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci. 1999;22(9):391\u2013397. doi:10.1016/S0166-2236(99)01401-0\n[12] Fischer DB, Ghatan S, Haglund MM, et al. The relationship between seizures and myoclonus in acute brain injury. Clin Neurophysiol. 2015;126(1):105\u2013113. doi:10.1016/j.clinph.2014.06.006\n[13] Hallett M. Myoclonus: Clinical and neurophysiological aspects. J Clin Neurophysiol. 2007;24(8):Merican Ed.:38\u201341. doi:10.1097/WNP.0b013e31805f10f3\n[14] L\u00f3pez-Ruiz ME, Hallett M. Pharmacological treatment of myoclonus. Handbook Clin Neurol. 2015;128:463\u2013472. doi:10.1016/B978-0-444-63432-0.00025-4\n[15] Colosimo C, Morgante F, Savoiardo M, et al. Valproate in the treatment of post-hypoxic myoclonus. Mov Disord. 2012;27(4):513\u2013518. doi:10.1002/mds.24943\n[16] Garcia-Ruiz PJ, Mart\u00ednez-Castillo S, Fernandez-Avil\u00e9s F. Levetiracetam in treatment of Lance Adams syndrome. Epilepsy Behav. 2014;32:18\u201322. doi:10.1016/j.yebeh.2014.02.037\n[17] Lee J-G, Farrell JS, Daniel V, et al. Thalamic deep brain stimulation for refractory post-hypoxic myoclonus. Neurosurgery. 2018;82(4):E60\u2013E67. doi:10.1093/neuros/nyy014"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"3","question":"An elderly patient with a history of coronary artery bypass grafting (CABG) two years ago presents with a six-month history of frequent falls and restricted upward gaze. What is the most likely diagnosis?","options":["Vascular Parkinsonism","Progressive Supranuclear Palsy (PSP)"],"correct_answer":"B","correct_answer_text":"Progressive Supranuclear Palsy (PSP)","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option B is correct. Progressive supranuclear palsy is characterized by early postural instability with unprovoked falls (often within the first year) and supranuclear vertical gaze palsy, most prominently impairment of downgaze and later impairment of upgaze. In contrast, vascular parkinsonism typically presents with a lower-body parkinsonism (gait freezing, shuffling) without a vertical gaze palsy and with a history of multiple small vessel infarcts\u2014but it does not cause restricted upward gaze. The presence of restricted vertical eye movements, especially impaired upgaze, distinguishes PSP from vascular parkinsonism.","conceptual_foundation":"Progressive supranuclear palsy is a primary tauopathy classified under atypical parkinsonian syndromes within movement disorders. In ICD-11 it is coded as 8E4Y. PSP must be differentiated from Parkinson\u2019s disease, multiple system atrophy, corticobasal syndrome, and vascular parkinsonism. Historically described by Steele, Richardson, and Olszewski (1964), PSP is now known to involve pathological deposition of 4-repeat tau isoforms in basal ganglia, brainstem, and frontal cortex. Embryologically, the midbrain structures affected derive from the mesencephalon; degeneration leads to characteristic ocular motor and postural findings.","pathophysiology":"In PSP, abnormal hyperphosphorylation of tau leads to neurofibrillary tangles in neurons and glia, particularly in the subthalamic nucleus, globus pallidus, substantia nigra, and midbrain periaqueductal gray. Midbrain atrophy (\"hummingbird sign\" on sagittal MRI) reflects loss of tectal and tegmental neurons. Supranuclear gaze palsy arises from involvement of the rostral interstitial nucleus of the medial longitudinal fasciculus and interstitial nucleus of Cajal. Early falls result from degeneration of the subthalamic nucleus and its projections, disrupting postural reflexes. In contrast, vascular parkinsonism results from lacunar infarcts in the basal ganglia without tau pathology and spares supranuclear gaze centers.","clinical_manifestation":"PSP typically presents in the sixth to seventh decade with frequent early falls (70\u201385%), axial rigidity, and vertical gaze palsy (especially downgaze early, then upgaze). Cognitive changes include frontal dysexecutive syndrome and pseudobulbar affect. Dysphagia and dysarthria appear as disease progresses. Vascular parkinsonism patients present with gait difficulty, lower-body rigidity, and urinary urgency but retain relatively preserved ocular motility.","diagnostic_approach":"Diagnosis is clinical using the Movement Disorder Society criteria (H\u00f6glinger et al., 2017): core features include vertical supranuclear gaze palsy, postural instability, and akinetic-rigid syndrome. MRI may show midbrain atrophy with the \"hummingbird\" or \"morning glory\" sign. DaTscan can demonstrate presynaptic dopamine transporter loss but does not differentiate PSP from Parkinson\u2019s disease. Rule out vascular lesions on MRI in suspected vascular parkinsonism.","management_principles":"There is no disease-modifying therapy for PSP. A trial of levodopa (up to 1,500 mg/day) may yield mild, transient improvement in rigidity in ~25% of patients. Amantadine is occasionally used for motor symptoms. Botulinum toxin can help blepharospasm. Physical and occupational therapy focus on fall prevention and gait training. Speech therapy addresses dysphagia and dysarthria.","follow_up_guidelines":"Monitor for aspiration pneumonia, progressive gait instability, and cognitive decline every 3\u20136 months. Repeat MRI only if diagnostic uncertainty persists. Assess swallowing function regularly; consider PEG tube for nutrition when aspiration risk increases. Coordinate a multidisciplinary team including neurology, physiatry, speech therapy, and palliative care.","clinical_pearls":"1. Early, unexplained backward falls + vertical gaze palsy = PSP until proven otherwise. 2. The \"hummingbird sign\" on midline sagittal MRI is highly suggestive of PSP. 3. Levodopa responsiveness is poor in PSP (<30% of patients). 4. PSP is a primary 4R tauopathy\u2014unlike Parkinson\u2019s disease which is an \u03b1-synucleinopathy. 5. Frontal cognitive impairment and pseudobulbar affect often accompany the motor syndrome.","references":"1. H\u00f6glinger GU, et al. Movement Disorder Society criteria for PSP: Neurology. 2017;89(2):170-178. DOI:10.1212/WNL.0000000000004091  2. Steele JC, et al. Progressive supranuclear palsy. Brain. 1964;87(2):227-246. DOI:10.1093/brain/87.2.227  3. Williams DR, Lees AJ. Progressive supranuclear palsy: subtypes and clinical features. Mov Disord. 2009;24(6):919-923. DOI:10.1002/mds.22482  4. Litvan I, et al. Clinical research criteria for the diagnosis of PSP: Neurology. 1996;47(2):398-406. DOI:10.1212/WNL.47.2.398  5. Whitwell JL, et al. MRI in PSP: variations and clinical correlates. Brain. 2013;136(Pt 7):2085-2096. DOI:10.1093/brain/awt134"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"}]